Explain your diagnosis for the patient, including your rationale for the diagnosis. Describe an appropriate drug therapy plan based on the patient’s history, diagnosis, and drugs currently prescribed. Justify why you would recommend this drug therapy plan for this patient. Be specific and provide examples Drug Abuse and Possible Hepatitis Essay

Introduction

The symptoms present in patients experiencing gastrointestinal (GI) conditions are often non-specific, and it is important for care providers to conduct an extensive assessment to identify the underlying cause of the presentations. This process is further complicated by the fact that GI manifestations can occur on the background of diseases involving other systems. For example, patients with serious migraines frequently present with vomiting and nausea (Elliot et al., 2018). Hence, assessment of GI symptoms should be thoroughly performed on all system for both an accurate diagnosis and the appropriate therapeutic intervention. The paper will assess a case study involving GI manifestations, establish a diagnosis and rationale, and a treatment plan for the patient.

The case presents a patient with nausea, vomiting, and diarrhea, which are non-specific gastrointestinal symptoms. The patient has a confirmed history of drug abuse and suspected hepatitis C. However, the latter can only be placed as a diagnosis following a polymerase chain reaction (PCR) that identifies HCV RNA in the serum (Altaf et al., 2019; Ferri et al., 2016). Therefore, based on the medication history, the patient is suspected to be experiencing complications from the use of prednisone.

The side effects of prednisone on the GI tract have been well documented in scholarly literature due to their use in the management of different conditions. For example, patients that have been prescribed this drug have been found to have an elevated production of gastric acid within one month (Resanen, 2016). Furthermore, corticosteroids adversely impact the gastric mucosa, which further increases the risk of gastritis or gastric ulcers. These phenomena can be better understood through the mechanism of action of prednisone. This involves inhibition of phospholipid conversion to arachidonic acid, which stops prostaglandin production and its gastro protective functions (Caplan et al., 2017). This makes the gastric wall susceptible to the physiologically acidic pH of the stomach, leading to the manifestations displayed by the patient.

The general principles applied to minimize the side effects from oral glucocorticoids include a reassessment of their use and necessity for the patient, reducing the duration of use, and providing mucosal protective agents such as bismuth subsalicylate or sulcrafate. These agents help in coating areas of ulcers or erosion and preventing further damage from gastric acid. In the case of this patient bismuth subsalicylate will be selected agent as it also contributes to stimulating the secretion of mucus, prostaglandin, and bicarbonate (O’Malley, 2020). Patient education will also be provided, and include information on diet and different products that should be avoided while taking prednisone. Spicy and fried foods are not recommended, and smoking and alcohol should also be avoided as they irritate the gastric mucosa. The patient has a history of drug abuse, which makes education on abstaining from alcohol important as this can lead to ulcers, and gastric perforation, which is life threatening.

Summary

The paper discusses a patient that reports with non-specific gastrointestinal manifestations, a history of drug abuse, and currently synthroid, nifedipine, and prednisone. The preliminary diagnosis of the patient is gastritis on the background of prednisone use. This is a glucocorticoid, which affects the gastric mucosa through inhibition of prostaglandins. The drug bismuth subsalicylate was prescribed due to its mucosal protective properties. Other recommendations such as patient dietary education were also stated as certain food products can also affect the state of the mucosa and cause the existing manifestations to persist or lead to more life threatening situations.

 

 

 

References

Altaf, S., Tarar, A., & Naeem, N. (2019). Current Status of Therapeutics and Diagnosis of

HCV. BioScientific Review (BSR)1(2), 01-12.

Order this paper